- Linus Pauling PhD (1901-1994) Two times Nobel Prize winner.
The answer simply is YES. It only stands for logic and reason that the FDA and other cancer organizations at least attempt to investigate the claims that laetrile makes. There have been many tests over the last 40 years conducted on laetrile. This section will concentrate on a major 5 year study which was undertaken by America's number one Cancer Research department called Sloan Memmorial Ketering Cancer Reasearch (SMKR) Center in New York. In 1972 the SMKR commissioned their top senior cancer researcher to conduct tests over a 5 year period between 1972 and 1977and finally put an end to this laetrile quakery. They asked Dr Kanematsu Sugiura, their most senior researcher with over 60 years experience in cancer research and who had been under their employment since 1917 and totally dedicated to cancer research.
Dr Kanematsu Sugiura's work was trusted and his honesty and integrity was admired and unquestioned by all. Hundreds of Segiura's research papers were published. Dr Chester Stock, the Head of Sloan Kettering's laboratory-testing division even wrote:
"Few if any names in cancer research are as widely known as Kanematsu Segiura's....Possibly the highest regard in which his work is held is best characterised by a comment made to me by a visiting investigator in cancer research from Russia. He said "when Segiura publishes, we know we do not have to repeat the study, for we would obtain the same results he has reported"'.
At the conclusion of the trials, on June 15, 1977 the SMKCR released a press statement. Over 100 reporters and half a dozen film crews from the leading television stations had been assembled to hear the long awaited official verdict on laetrile from the worlds most prestigious cancer research centre. On the Dais were physicians with impeccable credentials. Dr Robert Good began to speak. After general remarks condemning laetrile and its use, he passed the microphone to Dr Stock. The same Doctor Chester Stock who had praised Segiura's work took the microphone and began describing the finer details of the testing. As his voice droned on... it was evident all eyes were on Dr Sugiura but he was not given the opportunity to speak.
The press release said, "...laetrile was found to possess neither preventative, nor tumor-regressent, nor anti-metastatic, nor curative anticancer activity."
So that is it then, right? It does not get more adamant than that, we can close the book on Laetrile. Unfortunately for the boss' at Sloan Kettering there was a large fly in the ointment. When suddenly a journalist shouted
"Dr. Kenamatsu Sugiura" ; "Do you stick by your belief that laetrile stops the spread of cancer?
He replied; "I stick."
Those two words must have been like knives to the accumulated demi-gods on the dais. The reason being is that Dr. Kanematsu Sugiura was the pre-eminent cancer researcher in America, probably the world, at this time. Dr. Sugiura had been researching cancer since 1911. It looked as if this quiet, highly respected researcher would slip quietly into anonymity. About ten years later, in the fall of 1972 he was asked by Sloan-Kettering to test Laetrile. Dr. Sugiura agreed. As Ralph Moss says in "The Cancer Industry";
"Because he had merely done what he was told and recorded what he saw, he lived to see old friends desert and berate him, a close relative fail to support him, and former colleagues derisively question his sanity and competence."
When asked "Why are they so much against it"? Dr Suigara answered "I don't know. Maybe the medical profession doesn't like it because they are making too much money."
Dr. Sugiura said, "The most interesting part is metastases. Secondary cancer growth to another location. When this mammary tumor grows to about two centimetres in diameter or more, about 80% develop lung metastases. But with treatment with laetrile/amygdalin, it's cut down to about 20%."
They didn't like it. Sugiura had to be proven wrong. But other researchers had obtained essentially the same positive results. Dr. Lloyd Schloen a biochemist at Sloan-Kettering had included proteolytic enzymes to his injections and reported 100% cure rate among his albino mice. This data had to be buried. They then then changed the protocols of the tests and amounts of Laetrile to make certain that they failed. Guess what, they failed, and that is what they reported.
The Conclusions of Sugiura's work were these:
1. Laetrile inhibited the growth of tumors
2. It stopped the spreading (metastasising) of cancer in mice
3. It relieved pain
4. It acted as a cancer preventative
5. It improved general health
Dr. Sugiura, with great courage, refused to accept this distortion of his factual record "I write what I see!" he declared. "Laetrile is a good palliative drug." He was hounded for doing so, a story Dr Ralph Moss tells in his book, The Cancer Industry. Dr Ralph Moss head of public relations at SMKR protested against this cover-up in numerous ways and he was fired in November, 1977 for "failing to carry out my most basic job responsibility, which means to lie when your boss tells you to".
Sloan-Ketterings motives were clearly revealed in the minutes of a meeting that top officials held on July 2, 1974. The discussions were private and candid. The only reason we know about them is that Representative John Kelsey, of the Michigan House of Representatives, obtained the minutes via a freedom of information act request some years later. The fact that numerous Sloan-Kettering officials were convinced of the effectiveness of amygdalin is obvious, they just weren't sure as to the extent of it's use. But they were not interested in further testing of this natural product. From "World Without Cancer"; The minutes read, quote,
"...Sloan-Kettering is not enthusiastic about studying amygdalin but would like to study CN (cyanide) releasing drugs."
Sloan-Kettering wanted a man-made patentable chemical to mimic the qualities found in amygdalin. That is where the money is. If a very effective cancer treatment or cure was found in the lowly apricot seed, it would spell economic disaster for the cancer industry.
Author Dr Ralph Moss worked at Sloan-Kettering during the amygdalin trials and went public on November 18, 1977, exposing the lies told by Sloan-Kettering about the laetrile/amygdalin trials. He was fired the next day.
Don't believe it? Research it for yourself - visit the references area